大阪大学 · 生化学・遺伝学・分子生物学
Fuminori Sakurai教授の研究室では、ウイルスベクターを用いた遺伝子治療やがん免疫療法の開発を柱としています。特にアデノウイルスやレオロウイルスをベースにしたがん治療用ウイルスの開発や、幹細幹細胞を用いたウイルス感染モデルの構築にも取り組んでいます。ヒトiPS細胞由来肝細胞を用いたB型肝炎ウイルスの感染モデルの確立も進めており、ウイルスと宿主の相互作用の解明を目的としています。
Figures are computed from collected data and may differ slightly.
We have recently developed a replication-defective, recombinant adenovirus (Ad) vector composed of the whole Ad serotype 35 (Ad35), a member of subgroup B. We describe herein the in vitro and in vivo gene transfer properties of Ad35 vector in comparison with Ad serotype 5 (Ad5) and the Ad5F35 vector, which is a fiber-substituted Ad5 vector containing Ad35 fiber proteins. In vitro, Ad35 vector efficiently transduced not only human CAR-positive cells but also CAR-negative cells. Following intraven
In order to understand the life cycle of hepatitis B virus (HBV) and to develop efficient anti-HBV drugs, a useful in vitro cell culture system which allows HBV infection and recapitulates virus-host interactions is essential; however, pre-existing in vitro HBV infection models are often problematic. Here, we examined the potential of human induced-pluripotent stem (iPS) cell-derived hepatocyte-like cells (iPS-HLCs) as an in vitro HBV infection model. Expression levels of several genes involved
Oncolytic reovirus, which possesses 10 segments of dsRNA genome, mediates antitumor effects via not only virus replication in a tumor cell-specific manner, but also activation of antitumor immunity; however, the mechanism(s) of reovirus-induced activation of antitumor immunity have not been fully elucidated. Recent studies have demonstrated that overcoming an immunosuppressive environment in tumor-bearing hosts is important to achieve efficient activation of antitumor immunity. Among the various
Open papers in the app to read, cite, and organize with AI.
